The wellness offering utilizes advanced genetics to provide personalized risk information for common and preventable diseases, including heart disease, diabetes, breast and prostate cancer

We are delighted to share exciting news in cardiovascular prevention! Genomics plc's study in the European Journal of Preventive Cardiology integrates genetic risk factors for advanced heart disease prediction with QRISK®2. This HEART Study demonstrates that Integrated Risk Tools (IRTs) are a potent combination outperforming existing tools.

An article in The Financial Times by Hannah Kuchler announced the news of the Oxford university spinout's successful fundraise to help predict disease leveraging polygenic risk scores.

Genomics plc has been selected from among more than 1,500 applications to be included in Bloomberg’s inaugural 25 UK Startups to Watch list. Bloomberg canvassed the UK to find 25 startups that represent the diversity and innovation of the country's startup scene. The Editors wanted to hear about companies that are growing fast, working on something truly unique and come from a diverse group of founders from all over the UK. Genomics plc co-Founder, Professor Sir Peter Donnelly, was also one of three founders from companies in the list to be on stage at the Bloomberg Technology Summit to discuss the Genomics plc story and the wider life sciences/tech sector.

Genomics plc has made it into the Newsweek list of the UK's 100 Most Loved Workplaces 2023. The list is based on feedback from companies' employees and the rankings encompass a company's commitment to equality, diversity and inclusion, its dedication to employee growth and development and its ability to adapt to the needs of its workforce.

An article in The Guardian by Hannah Devlin on our HEART study looking at polygenic risk scores for the prevention of common diseases like cardiovascular disease.

The NHS and UK biotech company Genomics plc have announced a pilot study that aims to more accurately predict patients’ risk of heart disease using a new integrated polygenic and clinical risk tool.

Empowering Drug Discovery through Genomics

The wellness offering utilizes advanced genetics to provide personalized risk information for common and preventable diseases, including heart disease, diabetes, breast and prostate cancer

We are delighted to share exciting news in cardiovascular prevention! Genomics plc's study in the European Journal of Preventive Cardiology integrates genetic risk factors for advanced heart disease prediction with QRISK®2. This HEART Study demonstrates that Integrated Risk Tools (IRTs) are a potent combination outperforming existing tools.

An article in The Financial Times by Hannah Kuchler announced the news of the Oxford university spinout's successful fundraise to help predict disease leveraging polygenic risk scores.

Genomics plc has been selected from among more than 1,500 applications to be included in Bloomberg’s inaugural 25 UK Startups to Watch list. Bloomberg canvassed the UK to find 25 startups that represent the diversity and innovation of the country's startup scene. The Editors wanted to hear about companies that are growing fast, working on something truly unique and come from a diverse group of founders from all over the UK. Genomics plc co-Founder, Professor Sir Peter Donnelly, was also one of three founders from companies in the list to be on stage at the Bloomberg Technology Summit to discuss the Genomics plc story and the wider life sciences/tech sector.

Genomics plc has made it into the Newsweek list of the UK's 100 Most Loved Workplaces 2023. The list is based on feedback from companies' employees and the rankings encompass a company's commitment to equality, diversity and inclusion, its dedication to employee growth and development and its ability to adapt to the needs of its workforce.

An article in The Guardian by Hannah Devlin on our HEART study looking at polygenic risk scores for the prevention of common diseases like cardiovascular disease.

The NHS and UK biotech company Genomics plc have announced a pilot study that aims to more accurately predict patients’ risk of heart disease using a new integrated polygenic and clinical risk tool.

Empowering Drug Discovery through Genomics

The wellness offering utilizes advanced genetics to provide personalized risk information for common and preventable diseases, including heart disease, diabetes, breast and prostate cancer

We are delighted to share exciting news in cardiovascular prevention! Genomics plc's study in the European Journal of Preventive Cardiology integrates genetic risk factors for advanced heart disease prediction with QRISK®2. This HEART Study demonstrates that Integrated Risk Tools (IRTs) are a potent combination outperforming existing tools.

An article in The Financial Times by Hannah Kuchler announced the news of the Oxford university spinout's successful fundraise to help predict disease leveraging polygenic risk scores.

Genomics plc has been selected from among more than 1,500 applications to be included in Bloomberg’s inaugural 25 UK Startups to Watch list. Bloomberg canvassed the UK to find 25 startups that represent the diversity and innovation of the country's startup scene. The Editors wanted to hear about companies that are growing fast, working on something truly unique and come from a diverse group of founders from all over the UK. Genomics plc co-Founder, Professor Sir Peter Donnelly, was also one of three founders from companies in the list to be on stage at the Bloomberg Technology Summit to discuss the Genomics plc story and the wider life sciences/tech sector.

Genomics plc has made it into the Newsweek list of the UK's 100 Most Loved Workplaces 2023. The list is based on feedback from companies' employees and the rankings encompass a company's commitment to equality, diversity and inclusion, its dedication to employee growth and development and its ability to adapt to the needs of its workforce.

An article in The Guardian by Hannah Devlin on our HEART study looking at polygenic risk scores for the prevention of common diseases like cardiovascular disease.

The NHS and UK biotech company Genomics plc have announced a pilot study that aims to more accurately predict patients’ risk of heart disease using a new integrated polygenic and clinical risk tool.

Empowering Drug Discovery through Genomics